The Great Unbalding

400,000 Men Watching Every Clinical Update in Real Time

In April 2026, New York Magazine ran a cover feature titled "The Great Unbalding," declaring that after decades of snake oil and broken promises, hair loss science had reached "a real inflection point."¹ The article centered on a drug called PP405 and the online community tracking its every move: the Tressless subreddit, a 400,000-member forum of men, many of them young, stunned that their follicles betrayed them before their 30th birthday.

The piece struck a nerve because it named something the clinical world has been quietly acknowledging for two years: the hair loss pipeline in 2026 is genuinely different from anything that came before. Not incrementally different. Mechanistically different. We covered finasteride and minoxidil in Issue #033, and clascoterone and rezpegaldesleukin in Issue #037. This issue tackles the two drugs the New York Magazine piece made famous that we haven't yet reviewed: PP405, a topical that claims to wake up dead follicles, and VDPHL01, an oral pill that tries to make minoxidil work the way it was always supposed to.

Pattern baldness, or androgenetic alopecia, affects roughly 80 percent of men and nearly half of women over a lifetime.² The global hair loss treatment market is projected to exceed $13 billion by 2028.³ And for most of that market's history, the science has been offering the same two drugs, approved in the 1980s and 1990s, that slow the decline without reversing it. That is what makes PP405 and VDPHL01 worth examining carefully. They are not just new drugs. They represent genuinely new ideas about what a hair loss treatment should do.

Two Drugs, Three Decades, and the Same Ceiling

To understand why PP405 and VDPHL01 matter, you need to understand what they're replacing. Minoxidil, approved in 1988, was originally a blood pressure drug. Someone noticed that patients grew more hair. The topical version, branded as Rogaine, became the first FDA-approved hair loss treatment. It works by dilating blood vessels around hair follicles, extending the growth phase. But it doesn't address the underlying cause of androgenetic alopecia, and it requires indefinite twice-daily application. Stop using it, and the hair you gained falls out within months.⁴

Finasteride, approved in 1997 as Propecia, blocks the enzyme that converts testosterone into dihydrotestosterone, or DHT, the hormone that miniaturizes hair follicles. It is more effective than minoxidil for many men, but it carries well-documented risks: decreased libido, erectile dysfunction, and in rare cases, persistent sexual side effects even after discontinuation.⁵ For women, finasteride is largely off the table due to teratogenicity risks.

Both drugs share a fundamental limitation. They can slow follicle miniaturization and, in some cases, thicken existing hairs. But neither can reliably reawaken follicles that have already gone dormant. Once a follicle stops producing visible hair, finasteride and minoxidil are essentially shouting at an empty house. This is the ceiling that PP405 and VDPHL01 are each trying to break through, by entirely different strategies.

PP405: Reprogramming Dormant Follicles From the Inside

PP405 was born at UCLA, where three researchers, Bill Lowry, Heather Christofk, and Michael Jung, spent nearly a decade studying why hair follicle stem cells go quiet.⁶ Their discovery was metabolic. In a healthy growth cycle, hair follicle stem cells rely on glycolysis, a fast, oxygen-independent way of generating energy. When follicles miniaturize and go dormant, those stem cells shift to oxidative phosphorylation, a slower metabolic pathway that keeps them alive but inactive. The cells aren't dead. They're in a kind of metabolic hibernation.

PP405 is a small-molecule inhibitor of the mitochondrial pyruvate carrier, or MPC, a protein that controls how pyruvate enters the mitochondria for energy generation.⁷ By blocking MPC, PP405 forces pyruvate to accumulate in the cell's cytoplasm, which stimulates lactate dehydrogenase activity and increases intracellular lactic acid. The stem cell's metabolism shifts back toward glycolysis, the state associated with active growth and tissue regeneration. In principle, this reactivates follicles that have already surrendered.

This is a genuinely novel mechanism. Finasteride blocks a hormone. Minoxidil dilates blood vessels. PP405 reprograms the metabolic identity of the stem cell itself. The UCLA team founded Pelage Pharmaceuticals in 2018 to develop the compound, and in October 2025, Time magazine named PP405 one of its Best Inventions of the year.⁸

The Phase 1 study, presented as late-breaking data at the American Academy of Dermatology meeting in 2024, had previously demonstrated that PP405 activates human hair follicle stem cells both ex vivo and in vivo.¹⁰ Pelage raised a $120 million Series B in October 2025 and presented additional data at AAD 2026, with Phase 3 trials planned to begin later this year.¹¹

VDPHL01: Making Minoxidil Safe Enough to Swallow

VDPHL01 takes the opposite approach. Rather than inventing a new molecule, Veradermics asked a deceptively simple question: what if we could make oral minoxidil work the way dermatologists have always wished it did?

Oral minoxidil has been an open secret in dermatology for years. At low doses, typically 1.25 to 5 milligrams, it produces stronger and more consistent hair growth than the topical version. Many dermatologists prescribe it off-label. But the immediate-release formulation creates a pharmacokinetic problem: plasma concentrations spike within one hour, cross into the range associated with cardiovascular effects, including tachycardia and fluid retention, and then crash back down within four hours. The drug spends too little time at hair-growth concentrations and too much time at cardiac-risk concentrations.¹²

VDPHL01 is an extended-release oral minoxidil tablet. The proprietary gel-matrix formulation delivers a slow, sustained release that keeps plasma levels above the roughly 1 to 2 nanograms per milliliter threshold needed for hair growth for up to 15 to 24 hours, while staying below the approximately 20 nanograms per milliliter level where cardiac effects begin.¹³ In pharmacokinetic terms, it flattens the curve: lower peak, longer duration, same drug.

Critically, VDPHL01 is non-hormonal. It does not affect DHT, testosterone, or any androgen pathway. This makes it viable for both men and women, which is significant because women currently have no FDA-approved oral treatment for pattern hair loss. Veradermics is positioning VDPHL01 as the potential first-ever FDA-approved oral treatment for female pattern hair loss, a market that has been functionally ignored by pharmaceutical development for decades.¹⁴

One Has 78 Patients. The Other Has 21. Both Want Your Optimism.

Let me be direct about where we are. PP405 has Phase 2a data in 78 patients after four weeks of treatment. VDPHL01 has Phase 2 data in 21 patients in an open-label study with no placebo group. Neither drug has published Phase 3 results. Neither drug has been submitted to the FDA. And neither drug has appeared in a peer-reviewed journal with full methodology and individual patient data.

That said, several features of the data are genuinely encouraging. PP405's responder analysis is notable: 31% of men with advanced hair loss saw meaningful density improvement at 8 weeks, versus 0% on placebo. Zero is a hard number to argue with in a placebo arm. The drug also appeared to generate new terminal hair in previously bald regions, not just thicken existing miniaturized hair, which is a qualitatively different outcome from anything finasteride or minoxidil has demonstrated.⁹

VDPHL01's pharmacokinetic story is compelling on paper. The extended-release approach to oral minoxidil addresses a real clinical problem. Dermatologists already know the drug works orally. They already prescribe it off-label. The barrier has always been the cardiovascular risk profile. If Veradermics can demonstrate that their formulation delivers hair growth without cardiac events in a 1,000-patient Phase 3 program, that would be genuinely practice-changing.¹³

But the pipeline is broader than two drugs. Cosmo Pharmaceuticals reported Phase 3 results for clascoterone 5% topical solution in late 2025, showing 539% relative improvement in hair count versus vehicle in one trial and 168% in the second, with an NDA planned for early 2027.¹⁷ Kintor Pharmaceutical is advancing GT20029, a topical PROTAC compound that degrades the androgen receptor rather than blocking it, into Phase 3.¹⁸ The landscape is more crowded, and more scientifically diverse, than at any point in the history of hair loss medicine.

Small Trials, Missing Journals, and the Hype-to-Data Ratio

The cardiovascular question for VDPHL01 deserves particular scrutiny. The company's argument rests on pharmacokinetic modeling: keep plasma levels below 20 nanograms per milliliter, avoid cardiac effects. But this threshold is derived from the original hypertension literature for minoxidil, not from prospective cardiac safety studies of the extended-release formulation. The Phase 2 study reported no cardiac adverse events, but 21 patients over four months is not a meaningful safety dataset for a drug whose parent compound has known cardiovascular toxicity.^12,15

For PP405, the mechanism is elegant but the long-term implications are uncertain. Forcing stem cells out of quiescence by altering mitochondrial metabolism is a powerful intervention. The safety profile in the short Phase 2a was clean, with no detectable systemic absorption. But the theoretical concern, selectively activating stem cell populations via metabolic reprogramming, warrants longer and larger studies before confidence is justified.⁹

Two Genuinely New Ideas. Zero Finished Phase 3 Trials.